GH Research (GHRS)
NASDAQ: GHRS
· Real-Time Price · USD
12.81
0.04 (0.27%)
At close: Aug 15, 2025, 12:50 PM
0.27% (1D)
| Bid | 12.6 |
| Market Cap | 794.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.11M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -17.55 |
| Forward PE | -8.18 |
| Analyst | Buy |
| Ask | 12.87 |
| Volume | 50,432 |
| Avg. Volume (20D) | 283,104.5 |
| Open | 12.73 |
| Previous Close | 12.78 |
| Day's Range | 12.35 - 12.84 |
| 52-Week Range | 6.00 - 20.50 |
| Beta | 0.98 |
About GHRS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GHRS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+10.98%
Shares of psychedelic companies are trading higher...
Unlock content with
Pro Subscription
1 month ago
+7.36%
Shares of psychedelic companies are trading higher following a report suggesting that the US Department of Health and Human Services Secretary Robert F. Kennedy Jr said the agency is committed to expanding research on the benefits of psychedelic therapy and is working with the FDA head to provide legal access for military veterans within 12 months.
3 weeks ago · proactiveinvestors.com
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidateatai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
3 weeks ago · proactiveinvestors.co.uk
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and es...
